Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Oncopeptides: Targeted oncology with commercial momentum - Edison

Oncopeptides

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved in Europe in 2022 for relapsed/refractory multiple myeloma (r/r MM) and is gaining traction across key geographies, notably Germany and Spain. The company reported net sales of SEK19.2m in Q225, a sizeable 135% increase year-on-year, reflecting the early impact of expanded commercial activities for the product. Current strategic priorities are focused on growing Pepaxti’s market presence (gearing up for commercialisation in Italy), advancing the development pipeline and achieving profitability by the end of 2026. Other key upcoming catalysts include potential partnerships in Japan for Pepaxti and further development of pipeline candidates such as OPD5.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.